Table 2 Treatment and outcomes of patients with adult-onset Still’s disease by age group.
From: Clinical characteristics and treatment of elderly onset adult-onset Still’s disease
Younger-onset (n = 36) < 65 years | Elderly onset (n = 26) ≥ 65 years | p | |
|---|---|---|---|
Treatment | |||
GCs | 35 (97.2%) | 26 (100%) | 0.39 |
Maximal dose (mg/kg/day) | 0.88 ± 0.26 | 0.93 ± 0.29 | 0.47 |
GCs pulse therapy | 26 (72.2%) | 20 (76.9%) | 0.67 |
GCs pulse therapy ≥ 3 times | 7 (19.4%) | 7 (26.9%) | 0.48 |
Time until GCs dose was halved (days) | 60.7 ± 25.3 | 72.8 ± 53.8 | 0.26 |
GCs only | 11 (30.6%) | 12 (46.2%) | 0.20 |
Methotrexate | 12 (33.3%) | 6 (23.1%) | 0.37 |
Tacrolimus | 6 (16.7%) | 2 (7.7%) | 0.11 |
Cyclosporine | 13 (36.1%) | 12 (46.2%) | 0.42 |
Tocilizumab | 8 (22.2%) | 7 (26.9%) | 0.66 |
Tumor necrosis factor-α inhibitors | 1 (2.8%) | 1 (3.8%) | 0.81 |
Plasma exchange | 11 (30.6%) | 4 (15.4%) | 0.16 |
Infection | |||
Cytomegalovirus | 5 (13.9%) | 10 (38.5%) | 0.025 |
Others | 4 (11.1%) | 4 (15.4%) | 0.62 |
Relapse | 11 (30.6%) | 10 (38.5%) | 0.51 |
Death | 1 (2.8%) | 2 (7.7%) | 0.37 |
